Network meta-analysis for deaths_(OS)

Network meta-analysis estimations pool direct and indirect evidences. These results should be considered as exploratory given the absence of assessment of transitivity assumption plausibility. Calculations by netmeta package.

T vs. C	Standard of Care (SoC)	carboplatin	gemcitabine	pegylated liposomal doxorubicin and cyclophosphamide	pembrolizumab alone	atezolizumab based treatment	olaparib
Standard of Care (SoC)	---	NA	NA	NA	1.03 0.91; 1.16	NA	1.11 0.81; 1.52
carboplatin	NA	---	NA	NA	NA	NA	NA
gemcitabine	NA	NA	---	NA	NA	NA	NA
pegylated liposomal doxorubicin and cyclophosphamide	NA	NA	NA	---	NA	NA	NA
pembrolizumab alone	0.97 0.86; 1.09	NA	NA	NA	---	NA	1.08 0.77; 1.50
atezolizumab based treatment	NA	NA	NA	NA	NA	---	NA
olaparib	0.90 0.66; 1.23	NA	NA	NA	0.93 0.66; 1.30	NA	---

pathologies: 140 - treatments: 483 result logic